Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus QUIDE.
MELLARIL vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic
Antipsychotic